MENU
+Compare
INMB
Stock ticker: NASDAQ
AS OF
Sep 3, 04:59 PM (EDT)
Price
$1.96
Change
-$0.01 (-0.51%)
Capitalization
52.37M

INMB INmune Bio Forecast, Technical & Fundamental Analysis

INmune Bio Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INMB with price predictions
Sep 02, 2025

INMB's RSI Indicator entering oversold zone

The RSI Oscillator for INMB moved into overbought territory on September 02, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INMB advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INMB as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INMB entered a downward trend on September 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.814) is normal, around the industry mean (19.852). P/E Ratio (0.000) is within average values for comparable stocks, (51.814). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.136). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (322.082).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INMB is expected to report earnings to fall 69.52% to -31 cents per share on October 29

INmune Bio INMB Stock Earnings Reports
Q3'25
Est.
$-0.32
Q2'25
Missed
by $0.65
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.15
Q3'24
Missed
by $0.08
The last earnings report on August 07 showed earnings per share of -104 cents, missing the estimate of -40 cents. With 469.76K shares outstanding, the current market capitalization sits at 52.37M.
A.I. Advisor
published General Information

General Information

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHNMF0.160.01
+5.26%
Phenom Resources Corp
MAKSF4.550.05
+1.00%
Marks & Spencer Group Plc
FXLG40.02N/A
N/A
F.S. Bancorp
PRXXF18.93N/A
N/A
Paradox Interactive AB
TZROP2.11-0.99
-31.94%
Tzero Group Inc.

INMB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UNBX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UNBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
-2.96%
UNBX - INMB
51%
Loosely correlated
-2.34%
OGEN - INMB
44%
Loosely correlated
+1.94%
GBIO - INMB
36%
Loosely correlated
-0.33%
PROK - INMB
36%
Loosely correlated
-2.54%
OVID - INMB
35%
Loosely correlated
-3.91%
More